Welcome. Who is here? What is this?

Here's news and info about three primary blood cancers, Lymphoma, Myeloma and Leukemia with a decided patient's perspective.  I hope this helps whether you're newly diagnosed or veteran survivor.  

       Is this You?              This is me.            We're Not Alone!    

 Is this You cancer patient    Click This is me    We are not alone, cancer warriors
Check my:Link to my blog


Twitter Feed

Click my Social Media, good stuff

YouTube -- https://www.youtube.com/user/JackWhelanAdvocate Twitter -- https://twitter.com/JackWhelan Google+ -- http://www.google.com/+JackWhelanAdvocate Facebook -- https://www.facebook.com/jack.whelan.98031

AACR Legislative: Write your Congressmen!


Professional Research Advocacy


American Association for Cancer Research


 American Society of Clinical Oncology 


Alliance for Clinical Research Excellence and Safety


National Organization for Rare Diseases 

Rare Disease Legislative Advocates  

Research Advocacy Network 

Alliance for Clinical Trials Oncology, Jack Whelan member

Patient Advocates In

Society for Participatory Medicine

Health Advocate Code of Conduct and Professional Standards

WEGO Health Speakers Bureau 

Connect With Me At ExpertFile


Music and audio player

As seen or quoted on these TV stations

ABC Good Morning America CBS Sunday Morning 2 News 3 News 8 10 News 12 News WIDK 10 28 News KCOY KCAU 9 KILL TV3 KLTV 7 KMPH 26 KOTA 28 News America my FOX LIVE HD 5 blip 28 News FOX-25 FOX-5 NEWS-25HD KYTX-19 NBC4i NBC29 ABC 33-40 WAND 17HD WBAY 2 WBOC 16 WECT 6 WHBQ 13 WITN WLBT 3 WMCT 5 WRCB 3 WSET 13 WTOC 11 WTVM 9 WVUE 8

Education Network to Advance Clinical Trials


It's no secret that I'm a big advocate encouraging cancer patients to seriously consider Clinical Trials as a safe and effective treatment option for cancer, particular incurable blood cancers. There is much evidence that supports the theory that many of the emerging targeting biologic and small molecule agents can be safer than many conventional chemotherapies including alkylating agents and nucleoside analogs.  There are far too many myths and misconceptions surrounding Clinical Trials.  Accordingly, there is an urgent need to educate physicians, patients and caregivers about the current state of the art.   I'm working with the Education Network to Advance Cancer Clinical Trials as a webcast speaker.  Check out www.enaact.org for more info.  


From Has | On January 02, 2014 @05:36 am
Many thanks for those thtouhgs, Kerstin, that's very interesting.I think the validity of my assertion that anyone else using the dataset would know exactly what the data mean depends on the purpose for which someone else wants the raw data.You make a good point that if it's to get raw data from several studies for cross-study analyses, then the wiggle room inherent in SDTM is going to make life tricky, particularly if studies have come from different companies. For those cross-study analyses, I think you are right to pick me up on my assertion that the problems are largely solved. Having read your links, I agree that I was being a bit over optimistic there.It will be interesting to see if the CDISC SHARE initiative can help standardise things. I have to say I'm skeptical about the prospect of having any standard that's sufficiently flexible to be useful in the huge variety of different study designs that are always going to exist, and yet eliminates the wiggle room , but I'll watch developments with interest.However, if data recipients are receiving raw data only for the purposes of re-analysing a single study, then I think I stand by my assertion. Certainly it's been my own experience that if I'm receiving SDTM data from someone else, then provided they have done a good job of completing their define.xml document (and of course that's not always true!), I have no problem figuring out what the data mean and doing whatever analyses are needed. I don't think I saw anything in the documents you provided that convinces me otherwise, unless you think I've missed something important?

Leave a comment